HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance In Brief

This article was originally published in The Rose Sheet

Executive Summary

Church & Dwight Q1: Divesture of deodorant and toothpaste businesses is "not on our radar," CEO James Craigie says in response to analyst question during first quarter sales and earnings call May 9. U.S. consumer sales increased 5.5% to $314 mil., with gains in other segments "partially offset by lower toothpaste and antiperspirant sales," company says in earnings release. In Q2, Mentadent and Arm & Hammer toothpaste launches will be backed by new ad campaigns, while Nair lotions will have increased marketing support, Craigie says. Personal care products were down .2% to $130.2 mil. First quarter sales of $442.4 mil., representing a 5.2% increase, include $12.3 mil. from acquisition of a skin care operation in Brazil and Procter & Gamble's SpinBrush battery-operated toothbrush business (1"The Rose Sheet" Sept. 19, 2005, p. 6). Net income increased 7% to $39.9 mil. including $2.1 mil. pretax stock option charge, and operating profit was up 7.6% to $72.3 mil. including the stock option charge...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts